abrdn Healthcare Opportunities Fund
Sponsor: abrdn · Inception Jul 29, 2014 · Pays monthly
Market priceShare price
$17.93
-0.99% ($-0.18)
NAVAsset value per share
$19.21
as of Oct 14, 2026 · Nasdaq NAV symbol
Premium / discountPrice vs. assets
6.66% discount *
Indicative: latest price vs latest reported NAV
Distribution rate (price)Payout rate
11.38%
regular, annualised · on NAV 10.62%
Expense ratioAnnual cost
Not reported
no tagged fee table
LeverageBorrowing
Not reported
senior securities not tagged
Quote status: Market closed — last regular-session price · last trade Oct 16, 2026, 4:00 PM EDT (exchange time, ET) · retrieved Oct 16, 2026, 6:54 PM EDTRegular-session prices; extended-hours quotes are not displayed.
Full portfolio as filed on SEC Form N-PORT for the month ending Jun 30, 2026, filed Aug 28, 2026. 109 positions; weights are percent of net assets as reported. Weights sum to 100.0% — leverage, cash, derivatives and short positions mean totals need not equal 100%. This is a historical report, not a live portfolio.
Top 10 holdings
| # | Security | Type | Country | Weight | Value (USD) |
|---|---|---|---|---|---|
| 1 | UnitedHealth Group Inc | Equity | United States | 4.77% | $50.1M |
| 2 | VeraDermics Inc | Equity | United States | 4.13% | $43.5M |
| 3 | Abbott Laboratories | Equity | United States | 3.74% | $39.4M |
| 4 | Merck & Co Inc | Equity | United States | 3.46% | $36.4M |
| 5 | Medtronic PLC | Equity | Ireland | 3.35% | $35.2M |
| 6 | Thermo Fisher Scientific Inc | Equity | United States | 3.29% | $34.6M |
| 7 | VERADERMICS, INC. | Preferred | United States | 3.19% | $33.6M |
| 8 | Intuitive Surgical Inc | Equity | United States | 2.66% | $28M |
| 9 | CVS Health Corp | Equity | United States | 2.59% | $27.3M |
| 10 | Danaher Corp | Equity | United States | 2.53% | $26.6M |
Asset class
| Asset class | % net assets | Value |
|---|---|---|
| Debt | 9.42% | $99.1M |
| Equity (common) | 83.23% | $875M |
| Equity (preferred) | 5.91% | $62.1M |
| Short-term investment vehicle | 1.46% | $15.3M |
| Derivative (equity) | -0.02% | $-161K |
Country (top 12)
| Country (top 12) | % net assets | Value |
|---|---|---|
| United States | 90.15% | $948M |
| Ireland | 4.44% | $46.7M |
| Netherlands | 2.18% | $22.9M |
| France | 1.32% | $13.9M |
| Switzerland | 0.91% | $9.5M |
| United Kingdom | 0.50% | $5.3M |
| Cayman Islands | 0.37% | $3.9M |
| Luxembourg | 0.13% | $1.4M |
| Canada | 0.00% | $9.9K |
Region
| Region | % net assets | Value |
|---|---|---|
| United States | 90.15% | $948M |
| Developed Europe | 9.48% | $99.7M |
| Offshore domiciles | 0.37% | $3.9M |
| Canada | 0.00% | $9.9K |
Issuer type
| Issuer type | % net assets | Value |
|---|---|---|
| Corporate | 92.27% | $970M |
| Other | 6.27% | $65.9M |
| Registered fund | 1.46% | $15.3M |
Fair-value level
| Fair-value level | % net assets | Value |
|---|---|---|
| Level 2 | 9.42% | $99.1M |
| Level 1 | 87.86% | $924M |
| Level 3 | 2.71% | $28.5M |
Level 3 = valued with unobservable inputs (typically private or illiquid).
Long / short
| Long / short | % net assets | Value |
|---|---|---|
| Long | 100.02% | $1.1B |
| N/A | -0.02% | $-161K |
All allocation percentages use net assets as the denominator (N-PORT convention). A position's share of invested assets may differ from its share of the whole fund including cash and leverage.
All 109 positions
| Security | Identifier | Type | Issuer | Country | Balance | Units | Value (USD) | Weight | FV level |
|---|---|---|---|---|---|---|---|---|---|
| UnitedHealth Group Inc | 91324P102 | Equity | CORP | United States | 120,631 | shares | $50.1M | 4.77% | 1 |
| VeraDermics Inc | 922967104 | Equity | CORP | United States | 353,716 | shares | $43.5M | 4.13% | 1 |
| Abbott Laboratories | 002824100 | Equity | CORP | United States | 433,683 | shares | $39.4M | 3.74% | 1 |
| Merck & Co Inc | 58933Y105 | Equity | CORP | United States | 283,202 | shares | $36.4M | 3.46% | 1 |
| Medtronic PLC | IE00BTN1Y115 | Equity | CORP | Ireland | 449,937 | shares | $35.2M | 3.35% | 1 |
| Thermo Fisher Scientific Inc | 883556102 | Equity | CORP | United States | 68,956 | shares | $34.6M | 3.29% | 1 |
| VERADERMICS, INC. | — | Preferred | CORP | United States | 273,261 | shares | $33.6M | 3.19% | 1 |
| Intuitive Surgical Inc | 46120E602 | Equity | CORP | United States | 70,415 | shares | $28M | 2.66% | 1 |
| CVS Health Corp | 126650100 | Equity | CORP | United States | 263,513 | shares | $27.3M | 2.59% | 1 |
| Danaher Corp | 235851102 | Equity | CORP | United States | 139,737 | shares | $26.6M | 2.53% | 1 |
| Oruka Therapeutics Inc | 687604108 | Equity | CORP | United States | 250,767 | shares | $23.9M | 2.27% | 1 |
| uniQure NV | NL0010696654 | Equity | CORP | Netherlands | 496,969 | shares | $22.9M | 2.18% | 1 |
| Humana Inc | 444859102 | Equity | CORP | United States | 57,188 | shares | $22.7M | 2.16% | 1 |
| Elevance Health Inc | 036752103 | Equity | CORP | United States | 54,645 | shares | $21.1M | 2.01% | 1 |
| BioCryst Pharmaceuticals Inc | 09058V103 | Equity | CORP | United States | 2,088,571 | shares | $20.9M | 1.99% | 1 |
| AbbVie Inc | 00287Y109 | Equity | CORP | United States | 80,912 | shares | $20.4M | 1.94% | 1 |
| Boston Scientific Corp | 101137107 | Equity | CORP | United States | 465,063 | shares | $19.8M | 1.89% | 1 |
| Sarepta Therapeutics Inc | 803607100 | Equity | CORP | United States | 921,334 | shares | $16.6M | 1.57% | 1 |
| NeoGenomics Inc | 64049M209 | Equity | CORP | United States | 1,069,634 | shares | $15.6M | 1.48% | 1 |
| Insulet Corp | 45784P101 | Equity | CORP | United States | 101,696 | shares | $15.5M | 1.47% | 1 |
| State Street Global Advisors | 857492706 | Short-term inv. | RF | United States | 15,337,270 | shares | $15.3M | 1.46% | 1 |
| Praxis Precision Medicines Inc | 74006W207 | Equity | CORP | United States | 43,765 | shares | $14.7M | 1.39% | 1 |
| ARS Pharmaceuticals Inc | 82835W108 | Equity | CORP | United States | 1,805,535 | shares | $14.5M | 1.38% | 1 |
| Abivax SA | 00370M103 | Equity | CORP | France | 104,341 | shares | $13.9M | 1.32% | 1 |
| Alignment Healthcare Inc | 01625V104 | Equity | CORP | United States | 577,052 | shares | $13.7M | 1.31% | 1 |
| Omega Healthcare Investors Inc | 681936100 | Equity | OTHER | United States | 278,033 | shares | $13.3M | 1.26% | 1 |
| Welltower Inc | 95040Q104 | Equity | OTHER | United States | 57,915 | shares | $13.1M | 1.25% | 1 |
| Vericel Corp | 92346J108 | Equity | CORP | United States | 294,506 | shares | $13.1M | 1.25% | 1 |
| Bristol-Myers Squibb Co | 110122108 | Equity | CORP | United States | 221,600 | shares | $12.8M | 1.21% | 1 |
| Molina Healthcare Inc | 60855R100 | Equity | CORP | United States | 52,318 | shares | $12M | 1.14% | 1 |
| GeneDx Holdings Corp | 81663L200 | Equity | CORP | United States | 171,640 | shares | $11.8M | 1.12% | 1 |
| Acadia Healthcare Co Inc | 00404A109 | Equity | CORP | United States | 353,243 | shares | $10.4M | 0.99% | 1 |
| Healthpeak Properties Inc | 42250P103 | Equity | OTHER | United States | 485,067 | shares | $10.4M | 0.99% | 1 |
| ABBOTT LABORATORIES | 002824BG4 | Debt | CORP | United States | 10,498,000 | principal | $10.2M | 0.97% | 2 |
| Charles River Laboratories International Inc | 159864107 | Equity | CORP | United States | 44,454 | shares | $10.1M | 0.96% | 1 |
| Ventas Inc | 92276F100 | Equity | OTHER | United States | 110,408 | shares | $9.8M | 0.93% | 1 |
| Oculis Holding AG | CH1242303498 | Equity | CORP | Switzerland | 688,455 | shares | $9.5M | 0.91% | 1 |
| Zoetis Inc | 98978V103 | Equity | CORP | United States | 131,249 | shares | $9.4M | 0.90% | 1 |
| Sabra Health Care REIT Inc | 78573L106 | Equity | OTHER | United States | 482,214 | shares | $9.4M | 0.89% | 1 |
| Biodesix Inc | 09075X207 | Equity | CORP | United States | 395,315 | shares | $8.9M | 0.85% | 1 |
| Stryker Corp | 863667101 | Equity | CORP | United States | 27,571 | shares | $8.7M | 0.83% | 1 |
| CIGNA GROUP/THE | 125523CD0 | Debt | CORP | United States | 8,250,000 | principal | $8.7M | 0.82% | 2 |
| ICON PLC | IE0005711209 | Equity | CORP | Ireland | 49,689 | shares | $8.6M | 0.82% | 1 |
| JOHNSON & JOHNSON | 478160BV5 | Debt | CORP | United States | 10,130,000 | principal | $8.1M | 0.77% | 2 |
| PFIZER INC | 717081ET6 | Debt | CORP | United States | 8,100,000 | principal | $7.9M | 0.75% | 2 |
| GE HealthCare Technologies Inc | 36266G107 | Equity | CORP | United States | 121,807 | shares | $7.8M | 0.74% | 1 |
| Waters Corp | 941848103 | Equity | CORP | United States | 20,517 | shares | $7.7M | 0.73% | 1 |
| McKesson Corp | 58155Q103 | Equity | CORP | United States | 9,893 | shares | $7.5M | 0.71% | 1 |
| Myriad Genetics Inc | 62855J104 | Equity | CORP | United States | 1,308,933 | shares | $7.5M | 0.71% | 1 |
| Disc Medicine Inc | 254604101 | Equity | CORP | United States | 100,151 | shares | $7.3M | 0.70% | 1 |
| IQVIA Holdings Inc | 46266C105 | Equity | CORP | United States | 36,599 | shares | $7.1M | 0.67% | 1 |
| Repligen Corp | 759916109 | Equity | CORP | United States | 48,404 | shares | $6.6M | 0.63% | 1 |
| THERMO FISHER SCIENTIFIC | 883556CY6 | Debt | CORP | United States | 6,500,000 | principal | $6.4M | 0.61% | 2 |
| Arcus Biosciences Inc | 03969F109 | Equity | CORP | United States | 207,838 | shares | $6.4M | 0.61% | 1 |
| Inspire Medical Systems Inc | 457730109 | Equity | CORP | United States | 140,853 | shares | $6.3M | 0.60% | 1 |
| Becton Dickinson & Co | 075887109 | Equity | CORP | United States | 39,575 | shares | $6M | 0.57% | 1 |
| Mineralys Therapeutics Inc | 603170101 | Equity | CORP | United States | 221,516 | shares | $6M | 0.57% | 1 |
| THIRD ARC BIO, INCrestricted | — | Preferred | CORP | United States | 2,718,372 | shares | $5.7M | 0.54% | 3 |
| UNITEDHEALTH GROUP INC | 91324PEV0 | Debt | CORP | United States | 5,800,000 | principal | $5.7M | 0.54% | 2 |
| ZIMMER BIOMET HOLDINGS | 98956PAG7 | Debt | CORP | United States | 6,000,000 | principal | $5.5M | 0.52% | 2 |
| LTC Properties Inc | 502175102 | Equity | OTHER | United States | 139,352 | shares | $5.4M | 0.51% | 1 |
| ASTRAZENECA PLC | 046353AD0 | Debt | CORP | United Kingdom | 4,750,000 | principal | $5.3M | 0.50% | 2 |
| ELEVANCE HEALTH INC | 036752AP8 | Debt | CORP | United States | 5,800,000 | principal | $5.3M | 0.50% | 2 |
| CIGNA GROUP/THE | 125523CM0 | Debt | CORP | United States | 5,800,000 | principal | $5.2M | 0.50% | 2 |
| UNITEDHEALTH GROUP INC | 91324PEJ7 | Debt | CORP | United States | 4,916,000 | principal | $4.8M | 0.45% | 2 |
| GLYCOMINE, INC.restricted | — | Preferred | CORP | United States | 7,417,198 | shares | $4.5M | 0.42% | 3 |
| CRYSTALYS THERAPEUTICS SER Arestricted | — | Preferred | CORP | United States | 4,180,265 | shares | $4.2M | 0.40% | 3 |
| Lucid Diagnostics Inc | 54948X109 | Equity | CORP | United States | 3,822,997 | shares | $4.1M | 0.39% | 1 |
| MERCK & CO INC | 58933YAX3 | Debt | CORP | United States | 4,000,000 | principal | $3.9M | 0.37% | 2 |
| Perceptive Capital Solutions Corp | KYG700771051 | Equity | CORP | Cayman Islands | 355,447 | shares | $3.9M | 0.37% | 1 |
| CareDx Inc | 14167L103 | Equity | CORP | United States | 128,795 | shares | $3.7M | 0.35% | 1 |
| ATALANTA THERAPEUTICSrestricted | — | Preferred | CORP | United States | 4,636,752 | shares | $3.7M | 0.35% | 3 |
| ENDEAVOR BIOMEDICINES, INC.restricted | — | Preferred | CORP | United States | 742,138 | shares | $3.5M | 0.33% | 3 |
| STRYKER CORP | 863667AQ4 | Debt | CORP | United States | 3,500,000 | principal | $3.5M | 0.33% | 2 |
| SEISMIC THERAPEUTICS, INC.restricted | — | Preferred | CORP | United States | 730,764 | shares | $3.3M | 0.31% | 3 |
| CVS HEALTH CORP | 126650CZ1 | Debt | CORP | United States | 3,700,000 | principal | $3.3M | 0.31% | 2 |
| ELEVANCE HEALTH INC | 036752AG8 | Debt | CORP | United States | 2,975,000 | principal | $3M | 0.28% | 2 |
| PFIZER INC | 717081EC3 | Debt | CORP | United States | 3,200,000 | principal | $2.9M | 0.28% | 2 |
| Tandem Diabetes Care Inc | 875372203 | Equity | CORP | United States | 192,312 | shares | $2.9M | 0.28% | 1 |
| SpyGlass Pharma Inc | 85220G109 | Equity | CORP | United States | 129,589 | shares | $2.9M | 0.27% | 1 |
| Dexcom Inc | 252131107 | Equity | CORP | United States | 42,503 | shares | $2.9M | 0.27% | 1 |
| Alkermes PLC | IE00B56GVS15 | Equity | CORP | Ireland | 54,000 | shares | $2.8M | 0.27% | 1 |
| Diversified Healthcare Trust | 25525P107 | Equity | OTHER | United States | 293,879 | shares | $2.7M | 0.26% | 1 |
| Mobia Medical Inc | 60705V103 | Equity | CORP | United States | 199,584 | shares | $2.7M | 0.25% | 1 |
| ABBVIE INC | 00287YAW9 | Debt | CORP | United States | 3,080,000 | principal | $2.6M | 0.25% | 2 |
| Eli Lilly & Co | 532457108 | Equity | CORP | United States | 2,195 | shares | $2.6M | 0.25% | 1 |
| Sera Prognostics Inc | 81749D107 | Equity | CORP | United States | 1,355,853 | shares | $2.5M | 0.23% | 1 |
| ELEVANCE HEALTH INC | 94973VBK2 | Debt | CORP | United States | 2,325,000 | principal | $2M | 0.19% | 2 |
| Tenet Healthcare Corp | 88033G407 | Equity | CORP | United States | 10,692 | shares | $2M | 0.19% | 1 |
| CVS HEALTH CORP | 126650CY4 | Debt | CORP | United States | 2,100,000 | principal | $2M | 0.19% | 2 |
| Seaport Therapeutics Inc | 81221K108 | Equity | CORP | United States | 88,659 | shares | $1.9M | 0.18% | 1 |
| Revolution Medicines Inc | 76155X100 | Equity | CORP | United States | 8,754 | shares | $1.6M | 0.16% | 1 |
| Healthcare Realty Trust Inc | 42226K105 | Equity | OTHER | United States | 77,778 | shares | $1.6M | 0.15% | 1 |
| CIGNA GROUP/THE | 125523AH3 | Debt | CORP | United States | 1,504,000 | principal | $1.5M | 0.14% | 2 |
| DH EUROPE FINANCE II | 23291KAJ4 | Debt | CORP | Luxembourg | 1,760,000 | principal | $1.4M | 0.13% | 2 |
| ABCURO, INC.restricted | — | Preferred | CORP | United States | 601,124 | shares | $1.2M | 0.12% | 3 |
| Odyssey Therapeutics Inc | 67613T104 | Equity | CORP | United States | 48,400 | shares | $906K | 0.09% | 1 |
| Kailera Therapeutics Inc | 482931102 | Equity | CORP | United States | 40,727 | shares | $897K | 0.09% | 1 |
| ENDEAVOR BIOMEDICINES INC.restricted | — | Preferred | CORP | United States | 137,039 | shares | $894K | 0.09% | 3 |
| InspireMD Inc | 45779A846 | Equity | CORP | United States | 1,259,385 | shares | $882K | 0.08% | 1 |
| ABCURO INC.restricted | — | Preferred | CORP | United States | 133,045 | shares | $803K | 0.08% | 3 |
| ENGRAIL THERAPEUTICS INC. SERIrestricted | — | Preferred | CORP | United States | 1,652,502 | shares | $792K | 0.08% | 3 |
| Avalyn Pharma Inc | 05348Y105 | Equity | CORP | United States | 19,705 | shares | $649K | 0.06% | 1 |
| Hemab Therapeutics Holdings Inc | 423494103 | Equity | CORP | United States | 15,326 | shares | $563K | 0.05% | 1 |
| National Health Investors Inc | 63633D104 | Equity | OTHER | United States | 5,596 | shares | $427K | 0.04% | 1 |
| OCULIS HOLDINGS AG | — | Equity | CORP | United States | 22,433 | shares | $311K | 0.03% | 1 |
| CONTRA FUSION PHARMACErestricted | 361CVR012 | Equity deriv. | OTHER | Canada | 7,160 | shares | $9.9K | 0.00% | 3 |
| IO LIGHT HOLDINIGS, INC.restricted | — | Preferred | CORP | United States | 189,858 | shares | $19 | 0.00% | 3 |
| Options Clearing Corp. | — | Equity deriv. | OTHER | United States | -200 | contracts | $-171K | -0.02% | 1 |
Equities show share counts; bonds and loans show principal amount. Coupon, maturity and ratings are shown where the filing discloses them. Source: SEC N-PORT via market-data vendor re-serve, position-level.
Holdings reports on file
| Report date | Filed | Positions | Σ weight | Net assets (calc.) | Coverage |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 28, 2026 | 109 | 100.0% | $1.1B | full |
| Mar 31, 2026 | May 29, 2026 | 108 | 100.0% | $947M | full |
| Dec 31, 2025 | Feb 27, 2026 | 111 | 100.0% | $1B | full |
Net assets here are calculated from position values ÷ reported weights (median across positions), not a reported figure.
CEF Explorer research page for abrdn Healthcare Opportunities Fund. Figures carry their own dates and sources; a discount to NAV does not guarantee convergence or any return. This is not investment advice.